Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea, and Japan. Its world-class CLIA-certified laboratory in California has tested more than three million patients for COVID and RSV.
Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.
Gambale’s extensive experience will support Avellino’s bioinformatics precision medicine mission.
Avellino and Keeler, a global ophthalmic device manufacturer and distributor, have entered into an agreement where Keeler will distribute AvaGen on its US website. AvaGen
Avellino has launched an expanded AvellinoCoV2 – Respiratory Test that now detects respiratory syncytial virus (RSV). The test supports an unprecedented RSV, cold and flu
Avellino, one of California’s largest Covid-19 test providers, and the Hayward Fire Department celebrated the two-year anniversary of their joint effort opening the first free,
Globally Recognized Scientific Policy and Genomics Expert Genya Dana, Ph.D. Joins Avellino as Global Head of Health Policy
Dana’s abundance of policy experience in genomics and biotechnology will help lead Avellino’s next chapter of growth as the company continues to develop its powerful
Omicron Surge Prompts Opening of New Drive-Through Community Covid Testing Site by Leading Bay Area Covid Test Provider
Avellino, one of California’s largest COVID test providers, has opened a new drive-through COVID-19 testing site at its company headquarters in Menlo Park, CA to
Dr. Yeu’s depth of experience will help Avellino as the company continues to provide genetic-based diagnostics for the ophthalmic industry and expands its innovative product
Avellino Lab USA, Inc. (Avellino) is pleased to announce Jon Robson as the company’s new CEO and member of the Board of Directors. Jon will
Avellino and Sugentech, Inc., a bio- and nano- based technology and in-vitro diagnostic firm based in Korea, as part of their partnership agreement announced in
Avellino today announced that more than two million of its SARS-CoV-2/COVID-19 Tests (AvellinoCoV2) have now been performed in the United States. Avellino was one of
Avellino Launches AvaGenTM Nationwide as the First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophies
Avellino today announced full nationwide availability in the U.S. of AvaGen™, The Genetic Eye Test, as the first genetic test that helps determine a patient’s
Ahmad brings more than 22 years of experience to the role, with advanced knowledge of digital transformation, cloud technologies, big data, AI, and machine learning.
Former World Economic Forum Member of the Managing Board Murat Sönmez Joins Avellino’s Board of Directors
Avellino Lab USA, Inc. (Avellino) today announced the appointment of Murat Sönmez to the company’s Board of Directors. Murat is a former World Economic Forum
Avellino Donates $25,000 to National Keratoconus Foundation to Support World Keratoconus Day and Disease Education
Avellino Lab USA, Inc. (Avellino), in honor of World Keratoconus Day, today announced a $25,000 donation to the National Keratoconus Foundation (NKCF) to support their
Avellino announced today the appointment of three new members to its Board of Directors.
Avellino announced today that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the U.S. Food and Drug
Partnership Focused In Short Term On COVID-19 Genetic Diagnostics and Solutions, Long Term Collaboration On Partner Diagnostics and Therapeutics
The NBC Bay Area Investigative Unit was granted exclusive access inside Avellino Laboratory, a Menlo Park-based genetic research firm that designed its own test for
Avellino Lab USA Inc. has developed a diagnostic test for the novel coronavirus SARS-CoV-2, which has been validated in keeping with the U.S. Food and
Avellino Labs is proud to announce that it has received CLIA certification for AvaGen, a genetic diagnostic test for keratoconus and corneal dystrophies. With the
Avellino Labs announced the addition of William F. Stasior to the company’s Executive Advisory Committee and consultant to the company. Mr Stasior will advance Avellino
Avellino Labs, global biotechnology and genetic science innovators, announced Eric Bernabei as the company’s chief sales and marketing officer (CSMO). The addition of Bernabei will